Completion of the entire hepatitis C virus life cycle in genetically humanized mice

• Published in: Nature (London) 2013-09, Vol.501 (7466), p.237-241
• Main Authors: Dorner, Marcus, Horwitz, Joshua A., Donovan, Bridget M., Labitt, Rachael N., Budell, William C., Friling, Tamar, Vogt, Alexander, Catanese, Maria Teresa, Satoh, Takashi, Kawai, Taro, Akira, Shizuo, Law, Mansun, Rice, Charles M., Ploss, Alexander
• Format: Article
• Language: English
• Subjects: 631/326/596/1905; Animal models; Animals; Cell Line; Cyclophilin A - genetics; Cyclophilin A - metabolism; Disease Models, Animal; DNA sequencing; Genetic aspects; Genetic Engineering; Genomes; Hepacivirus - immunology; Hepacivirus - physiology; Hepatitis; Hepatitis C - genetics; Hepatitis C - immunology; Hepatitis C - virology; Hepatitis C virus; Human factors; Humanities and Social Sciences; Humans; Immune system; Infections; letter; Life cycles; Methods; Mice; Mice, Inbred C57BL; Mice, Transgenic; multidisciplinary; Nucleotide sequencing; Occludin - genetics; Occludin - metabolism; Rodents; Science; STAT1 Transcription Factor - deficiency; Tetraspanin 28 - genetics; Tetraspanin 28 - metabolism; Vaccines; Viremia - virology; Virion - growth & development; Virion - physiology; Virus Replication
• ISSN: 0028-0836; 1476-4687
• DOI: 10.1038/nature12427

The entire hepatitis C virus life cycle can be recapitulated in an inbred mouse model, allowing preclinical assessment of antiviral therapeutics and vaccines. Humanized mouse model for hepatitis C infection In a 2009 Nature paper, Alexander Ploss and colleagues showed that transient expression of the human genes CD81 and occludin ( OCLN ) constituted a minimal set of cellular factors required for uptake of hepatitis C virus (HCV) into immune-competent mouse cells. Now they report that transgenic immune-deficient mice stably expressing CD81 and OCLN can sustain the complete HCV replication cycle with measurable viraemia. The availability of this genetically humanized mouse model opens the way to closer study of HCV infection in vivo and should provide a valuable platform for testing potential therapeutics. More than 130 million people worldwide chronically infected with hepatitis C virus (HCV) are at risk of developing severe liver disease. Antiviral treatments are only partially effective against HCV infection, and a vaccine is not available. Development of more efficient therapies has been hampered by the lack of a small animal model. Building on the observation that CD81 and occludin (OCLN) comprise the minimal set of human factors required to render mouse cells permissive to HCV entry 1 , we previously showed that transient expression of these two human genes is sufficient to allow viral uptake into fully immunocompetent inbred mice 2 . Here we demonstrate that transgenic mice stably expressing human CD81 and OCLN also support HCV entry, but innate and adaptive immune responses restrict HCV infection in vivo . Blunting antiviral immunity in genetically humanized mice infected with HCV results in measurable viraemia over several weeks. In mice lacking the essential cellular co-factor cyclophilin A (CypA), HCV RNA replication is markedly diminished, providing genetic evidence that this process is faithfully recapitulated. Using a cell-based fluorescent reporter activated by the NS3-4A protease we visualize HCV infection in single hepatocytes in vivo . Persistently infected mice produce de novo infectious particles, which can be inhibited with directly acting antiviral drug treatment, thereby providing evidence for the completion of the entire HCV life cycle in inbred mice. This genetically humanized mouse model opens new opportunities to dissect genetically HCV infection in vivo and provides an important preclinical platform for testing and prioritizing d